# FIRE-3 (NCT00433927)

> 5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT00433927
- Phase: PHASE3
- Status: UNKNOWN
- Sponsor: PD Dr. med. Volker Heinemann
- Conditions: Neoplasm Metastasis; Colorectal Cancer
- Interventions: 5-FU; folinic acid; irinotecan; cetuximab; bevacizumab
- Enrollment: 568
- Primary outcome: Objective response rate

## Indexed commentary on FIRE-3 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 15
- YouTube: 9
- Podcasts: 5

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=fire-3-nct00433927

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT00433927", "email": "<work email>"}; the inbox owner confirms by the emailed link.